Certain clinical and morphologic observations are described in 35 necropsy patients with cardiac sarcoidosis (group IA and IB), and similar observations are summarized in 78 previously described necropsy patients with cardiac sarcoidosis (group IIA and IIB). All patients had non-necrotic (“hard”) granulomas in lymph nodes and either sarcoid granulomas in the heart (108 patients) or transmural myocardial scarring (five patients) unassociated with coronary arterial narrowing, i.e., healed granulomas. The 113 patients (groups I and II) whose data are analyzed also were divided into those in whom cardiac dysfunction clearly was the result of sarcoid granulomatous infiltration of the heart (89 patients) (groups IA and IIA), and those in whom cardiac dysfunction, if present, was clearly not the result of sarcoid involvement of the heart (24 patients) (groups IB and IIB). Analysis of the 89 patients in groups IA and IIA disclosed that death was sudden (arrhythmia) in 60 (67 per cent), secondary to progressive congestive cardiac failure in 20 (23 per cent), from recurring pericardial effusion in three (3 per cent) and from other or unknown causes in six (7 per cent). Sudden death was the initial manifestation of sarcoidosis in 10 (17 per cent) of the 60 patients who died suddenly. Other than premature ventricular beats, ventricular tachycardia was the most common arrhythmia (17 patients), and complete heart block was the most common conduction disturbance (25 patients). Complete bundle branch block occurred in 21 patients. Ventricular aneurysm (eight patients) and papillary muscle dysfunction (possibly 16 patients) were other cardiac disturbances observed. Although corticosteroid therapy tends to cause fibrous replacement of myocardial sarcoid granulomas, a possible consequence of this medication is the development of ventricular aneurysm. Most patients with cardiac sarcoidosis causing dysfunction (groups IA and IIA) presented initially with manifestations related to the heart. Furthermore, most patients with cardiac sarcoidosis have little or no clinical evidence of dysfunction of an organ system other than the heart. Usually the course in patients with extensive cardiac sarcoidosis is not prolonged.
Read full abstract